Showing results (91-100 of 197) with videos related to
Sort By:
Pageof 20
Journal of the American Academy of Dermatology|July 8, 2010
Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasisAlan Menter, Kenneth B Gordon, Craig L Leonardi, et al.The Journal of Dermatological Treatment|October 5, 2019
Characterization of insufficient responders to anti-tumor necrosis factor therapies in patients with moderate to severe psoriasis: real-world data from the US Corrona Psoriasis RegistryAbby S Van Voorhees, Marc A Mason, Leslie R Harrold, et al.Journal of the American Academy of Dermatology|March 19, 2011
Switching to adalimumab for psoriasis patients with a suboptimal response to etanercept, methotrexate, or phototherapy: efficacy and safety results from an open-label studyBruce E Strober, Yves Poulin, Francisco A Kerdel, et al.Journal of the American Academy of Dermatology|August 4, 2009
Psoriasis in patients with HIV infection: from the medical board of the National Psoriasis FoundationKavita Menon, Abby S Van Voorhees, Bruce F Bebo, et al.Archives of Dermatology|November 18, 2009
Alefacept for severe alopecia areata: a randomized, double-blind, placebo-controlled studyBruce E Strober, Kavita Menon, Amy McMichael, et al.Journal of the American Academy of Dermatology|August 20, 2022
Prospective cohort study of psoriatic arthritis risk in patients with psoriasis in a real-world psoriasis registryAlexis Ogdie, Ryan W Harrison, Robert R McLean, et al.Annals of the Rheumatic Diseases|May 8, 2012
Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's diseaseGerd R Burmester, Remo Panaccione, Kenneth B Gordon, et al.Blood|May 3, 2002
Differential abilities of central nervous system resident endothelial cells and astrocytes to serve as inducible antigen-presenting cellsAnn M Girvin, Kenneth B Gordon, C Jane Welsh, et al.Journal of the American Academy of Dermatology|August 9, 2016
Effects of tofacitinib on cardiovascular risk factors and cardiovascular outcomes based on phase III and long-term extension data in patients with plaque psoriasisJashin J Wu, Bruce E Strober, Peter R Hansen, et al.Dermatology and Therapy|July 29, 2025
Brodalumab: Seven-Year US Pharmacovigilance ReportMark G Lebwohl, John Y Koo, April W Armstrong, et al.Pageof 20